ICMR Collaborates for Innovative Phase-1 Clinical Trials in India
Groundbreaking Collaborations in Clinical Research
In a significant step towards bolstering India's clinical research capabilities, the Indian Council of Medical Research (ICMR) has signed Memorandum of Agreement (MoAs) with key industry players to conduct First-in-Human Phase-1 Clinical Trials for four promising therapeutic candidates under its Phase 1 Clinical Trial Network.
Key Partnerships and Innovations
- Aurigene Oncology: Collaborating on a small molecule for multiple myeloma.
- Indian Immunologicals Limited: Developing a vaccine for Zika.
- Mynvax Private Limited: Coordinating a seasonal influenza vaccine trial.
- ImmunoACT: Exploring advancements in CAR-T cell therapy for chronic lymphocytic leukemia.
Union Health Minister J P Nadda lauded the partnerships, calling them a pivotal step towards affordable healthcare and healthcare innovation in India.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.